Edesa Biotech, Inc. (EDSA) Social Stream



Edesa Biotech, Inc. (EDSA): $8.15

-0.49 (-5.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EDSA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

Featured Post From StockTwits About EDSA

$EDSA so one year ago the stock was at $19.10- wow. And then it came all the way back because not enough news was given? Is that correct?

Jul. 30, 2020, 10:47 AM
(RTTNews) - Shares of clinical-stage biopharmaceutical company Edesa Biotech, Inc. (EDSA) are surging more than 150% Thursday morning after the company said it has filed an investigational new drug (IND) application with the FDA to start phase II/III study of its drug candidate, EB05 in hospitalized Covid-19 patients.

The stock touched a new high of $19.10 this morning.

"The submission of the IND for EB05 in COVID-19 patients marks a key step in our plans to extend our planned Phase 2/3 study," said Dr. Par Nijhawan, Chief Executive Officer of Edesa. "We have received positive interest from key opinion leaders regarding our proposed clinical trial and are communicating with hospitals across the country regarding our protocol."
retirementsoon2, published August 15, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5878 seconds.